VCYT Q1 2025 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$114M+18.2% YoY

Gross Profit

$80M69.5% margin

Operating Income

$3M2.5% margin

Net Income

$7M6.2% margin

EPS (Diluted)

$0.09

QoQ Revenue Growth

-3.5%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$4M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$120M

Stockholders' Equity

$1.2B

Cash & Equivalents

$186M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$114M	$97M	+18.2%
Gross Profit	$80M	$62M	+27.3%
Operating Income	$3M	-$5M	+162.4%
Net Income	$7M	-$2M	+478.1%

Revenue Segments

Testing

$107M94%

Biopharmaceutical And Other

$4M3%

Product

$4M3%